FEATURED SLIDESHOW
Who Is The Worst CEO?Mad Money needed new inductees for its
Wall of Shame, so we asked viewers for
nominations.
RECENT POSTS
- Time to Buy Treasurys?
- Lightning Round: Las Vegas Sands, ADC Telecom, Satyam Computer and More
- Lightning Round OT: Knight Capital, Ebix and More
- Is Lear, Back From Bankruptcy, a Buy?
- Sanofi-Aventis Falling Off a Patent Cliff?
- Cramer: Your Thanksgiving Week Game Plan
- Cramer: Next Week Should Define Rest of ‘09
- Mad Money: Mad Mail: Buy RIM or Apple?
- Lightning Round: Cisco Systems, Citigroup, Baidu.com and More
- Lightning Round OT: Martek Biosciences, Valmont Industries and More
MAD MONEY FEATURES
PODCASTSWatch the Lightning Round whenever and wherever you want.
OFFICIAL MAD MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
CRAMERS SOUNDBOARDAdmit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.
CHECK OUT OUR PHOTOSCheck out Cramer on set, back to school, behind the scenes and more.
SHOP FOR MAD MERCHANDISEBuy Cramer books, bobbleheads and other Mad Money merchandise.
RING TONESPick up the phone! It's Cramer! New Mad Money sounds for your cell phone.
TEXT MESSAGE ALERTMad Money's mobile. Get show highlights sent to your phone.
Text Size 
News that Bear Stearns was scrambling for cash, reaching out to the Federal Reserve and JPMorgan Chase for emergency financing, killed the market Friday. The Dow dropped 195 points. But Cramer wasn’t going to let get in the way of his third anniversary show. Besides, he said, why bother with “some tale of woe that no one can possibly make a dime off.”
Instead he focused on drug stocks, a too-cheap sector that could make its return this fall. Maybe that sounds counterintuitive with the Democrats’ good chances of taking the White House. As Cramer pointed out, drug stocks were the market’s pariahs just before Bill Clinton took office. But pharma came back eventually. And the Mad Money host is expecting the same thing to happen again.
So what’s worth buying? Cramer said he likes Schering-Plough [SGP
Loading...
()
] for its overseas exposure and a few strong drugs, two of which SGP shares with Merck [MRK
Loading...
()
], Cramer’s other sector pick. He brushed off the Street’s concern about a patent challenge to Merck’s Nexium, prescribed for heartburn, saying the case has a one in 10 chance of going against the firm. And Merck’s new HPV vaccine for women could be worth $3 billion a year in sales.
Big pharma’s cheap for all the wrong reasons, Cramer said. When it comes back, you want Merck and Schering-Plough.
Don’t miss the guest appearance by Saturday Night Live's Darrell Hammond. Plus, audience questions about Teva Pharmaceuticals [TEVA
Loading...
()
] and stocks with safe dividends, and Cramer’s call on Gilead [GILD
Loading...
()
], Genentech [DNA
Loading...
()
], Celgene [CELG
Loading...
()
], Dow Chemical [DOW
Loading...
()
], ConEd [ED
Loading...
()
] and Carnival [CCL
Loading...
()
].
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?
Data is a real-time snapshot *Data is delayed at least 15 minutes